

Anti-Phospho-IKB alpha (Ser32/Ser36) Rabbit Polyclonal Antibody

Introduction

NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA (MIM 164014), or RELB (MIM 604758) to form the NFKB complex. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA or NFKBIB, MIM 604495), which inactivate NF-kappa-B by trapping it in the cytoplasm.

Product parameters

Alternative Names	NFKBIA; IKBA; MAD3; NFKBI; NF-kappa-B inhibitor alpha; I-kappa-B-alpha; IkB-alpha; IkappaBalpa; Major histocompatibility complex enhancer-binding protein MAD3
Gene ID	4792
Gene Name	NFKBIA
SwissProt ID	P25963
Host	Rabbit
Reactivity	Human, Mouse, Rat, Monkey
Molecular Weight	Calculated MW: 36 kDa; Observed MW: 36 kDa
Conjugation	Unconjugated
Ex	-
Em	-
Modification	Phosphorylated
Clonality	IgG
Isotype	Polyclonal Antibody
Clonality No.	-
Form	Liquid
Concentration	See label
Carrier	Carrier Not Free
Immunogen	The antiserum was produced against synthesized peptide derived from human IkappaB-alpha around the phosphorylation site of Ser32/Ser36.
Purification	Affinity Purified
Buffer System	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3.
Application	WB, IHC-F, IHC-P, ICC/IF, ELISA
Dilution Ratio	WB: 1/500-1/1000 IHC: 1/50-1/100 IF: 1/50-1/200 ELISA: 1/10000
Research Field	Epigenetics and Nuclear Signaling
Product Categories	Primary antibody

Shipping	Blue ice
Storage	-20°C
Expiration Date	12 months
Note	Please avoid freeze-thaw cycles.

Protocol



Configure the product according to the application range and recommended dilution ratio.

***Note:** The primary antibody dilution buffer options: WB - Primary Antibody Dilution Buffer (Cat. #: K1200, Not for HRP/AP conjugated antibodies), Immunostaining - Immunol Staining Primary Antibody Dilution Solution (Cat. #: K4655).

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

